2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)
Ian Chau(Royal Marsden Hospital), B.C. Cho(Yonsei University), M-H. Chen(Taipei Veterans General Hospital), Kenji Muro(Aichi Cancer Center), Lucjan Wyrwicz(National Institute of Oncology), Bo Li(Shandong First Medical University), Shuang Gao(Henan University of Science and Technology), C-H. Hsu(National Taiwan University Hospital), Anthony Turpin(Lille’s Cardiology Hospital), F. Lordick(University Hospital Leipzig), Edward Cha(Kaiser Permanente South San Francisco Medical Center), Qiong Wu(Roche (China)), Suzy Kim(Gene Therapy Laboratory), Jinquan Cai(Roche (China)), L. Zhang(Roche (China)), Jiawen Fan(Roche (China)), Li Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Karyn A. Goodman(Icahn School of Medicine at Mount Sinai), Manish A. Shah(Presbyterian Hospital), R-H. Xu(State Key Laboratory of Oncology in South China)
Cited by 6
Abstract
Related Papers
No related papers found
Powered by citation graph analysis